D ynavax Technologies has revealed promising topline outcomes from the initial part of its Phase I/II clinical trial, ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Shares in Dynavax Technologies Corporation closed 5% higher Thursday after the presentation of positive top-line results from ...

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified. See what to expect from GSK's Q3.

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy (respiratory syncytial virus [RSV] vaccine, adjuvanted) and Shingrix (zoster ...

GSK PLC GSK 1.14% extended its collaboration with Chongqing Zhifei Biological Products 300122 1.89% to commercialize its shingles vaccine Shingrix in China until 2034. The British pharma company ...

GSK's vaccines business has been held back by declining sales of shingles vaccine Shingrix in the United States and China, and a weaker than expected third quarter for RSV sales in the United States.